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Introduction {#sec1}
============

Pancreatic cancer (PC) is a highly malignant tumor, and the main pathological type is pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 80% of pancreatic tumors ([@bib75]). As one of the most malignant tumors, PC has a 5-year survival rate of less than 9%, and the prognosis is extremely poor ([@bib77]). More than 80% patients are in advanced stage at the time of diagnosis and unable to undergo radical resection due to the high incidence of invasion and metastasis ([@bib89]; [@bib61]). These malignant activities of PDAC may be due to the potent immunosuppressive microenvironment ([@bib43]; [@bib101]). High accumulation of immunosuppressive cells such as regulatory T lymphocytes (Tregs) has been found in the tumor microenvironment in patients with PDAC ([@bib35]; [@bib62]). Treg-associated immunosuppressive phenotypes, which play a crucial part in warding off the host immune system ([@bib20]; [@bib15]), also function in tumor initiation and progression ([@bib2]; [@bib34]). The increased Treg component in PC tissues and circulating blood is associated with poorly differentiated grade and reduced survival ([@bib36]; [@bib33]). Thus the interaction between cancer cells and Tregs in the tumor microenvironment has attracted attention.

Exosomes are extracellular vesicles (EVs) with a diameter of 50--150 nm that protect the contained biological cargo from degradation and denaturation in the extracellular environment. Exosomes play key roles in various physiological and pathological processes ([@bib65]; [@bib42]; [@bib10]; [@bib58]). As potent intercellular communicators, exosomes are secreted by many kinds of cells and are taken up by select target cells ([@bib17]; [@bib66]). Exosomes are also involved in immunoregulation mechanisms, with roles in the regulation of antigen presentation, immune activation, immunosuppression, immune surveillance, and intercellular communication. Several studies have shown that exosomes are associated with the progression of PDAC. Emerging evidence has suggested that cancer-derived exosomes may participate in the establishment of an immunosuppressive environment ([@bib100]). PC-derived exosomes serve as coordinators of pancreatic tumor immune tolerance ([@bib100]). Our previous studies showed that miR-203 and miR-212-3P, contained in exosomes, inhibit the expression of Toll-like receptor 4 and regulatory factor X-associated protein in dendritic cells, respectively ([@bib102]; [@bib21]). However, whether PC-derived exosomes are involved in Treg induction in the tumor microenvironment is not clear.

Previous studies refer to the EVs with a diameter of 50--150 nm isolated from 100,000 × *g* as exosomes and EVs with a diameter \>150 nm (or \>200 nm) isolated from 10,000 × *g* as microvesicles. However, the most current methods for isolation of small EVs are not available for separate endosome-origin "exosomes" and plasma membrane-derived "ectosomes." Therefore, the International Society for Extracellular Vesicles suggested the use of the terms based on the size of the EVs ([@bib85]). In our study, we refer to the EVs of size \<200 nm as small size extracellular vesicles (sEVs) and EVs of size \>200 nm as large size extracellular vesicles (lEVs).

Tumor cells, considered as high-energy-consuming cells, compete with T cells for energy in the tumor microenvironment, which drives tumor suppression or progression ([@bib14]; [@bib80]). The reduction of nutrients in the tumor microenvironment is associated with impaired anti-tumor immune responses ([@bib57]). T cell subsets tend to undergo different metabolic programs to allow survival and function. Compared with other metabolic substrates, glucose is particularly important for the survival and proliferation of effector T cells (Teffs) ([@bib27]). Unlike Teffs, Tregs mainly use lipid metabolism and have elevated levels of AMP-activated protein kinase (AMPK) activation ([@bib59]). AMPK is an important regulator of energy homeostasis, which can inhibit the differentiation of Th1 and Th17 cells and enhance Treg through metabolic effects on fatty acid oxidation and glycolysis ([@bib38]; [@bib83]). However, another study on the metabolism of various CD4+ T cell subsets raises an opposite point. Upon activation, Th1, Th2, Th17, and Treg all increased their glycolytic rates ([@bib59]). Therefore, upon sEVs stimulation, the changes in metabolism and metabolic gene expression during T cell differentiation still need to be explored.

The lack of sufficient glucose in metabolic competition leads to T cell DNA damage and senescence ([@bib51]). However, Tregs exhibit greater resistance to DNA damage compared with Teffs ([@bib93]). Ataxia telangiectasia mutated protein kinase (ATM) is a key regulator for cell response to DNA damage and for genome stability, whereas accumulating evidence suggests that ATM has been involved in energy metabolism and autophagy via phosphorylating AMPK ([@bib67]; [@bib11]; [@bib22]). However, the role of activated ATM in T cell differentiation is still unknown. PC exhibits an immunosuppressive microenvironment based on Treg infiltration, which may be due to metabolic competition and the DNA damage response (DDR). Based on RNA sequencing (RNA-seq) data and gene set enrichment analysis (GSEA), we identified DDR and metabolism-related signaling pathways. It is interesting to explore the relationship between ATM and AMPK in Treg DDR and metabolic programming.

As a carrier of intercellular communication, the role of sEVs in tumor cell-induced T cell DNA damage and metabolic changes is still unknown. Here, we explored whether T lymphocytes take up PDAC-derived sEVs and examined the potential response. To discover the interaction between PDAC cells, sEVs, and T lymphocytes, we tracked the transfer of sEVs from human PDAC-derived BxPC-3 cells to healthy human peripheral blood-derived T lymphocytes, detected the Treg phenotype, and explored the changes of gene expression profiles. We examined signaling pathways that might induce Tregs, focusing on the DDR and metabolism-related signaling pathway. We found that DNA repair activation, metabolic alterations, and Treg induction are linked by the ATM-AMPK-Sirtuins-FOXOs axis.

Results {#sec2}
=======

Peripheral T Lymphocyte Cytotoxic Activity Is Impaired after Uptake of PC-Derived sEVs {#sec2.1}
--------------------------------------------------------------------------------------

We isolated sEVs from the supernatant of human pancreatic stellate cell line HPaSteC (HPSC) and human PDAC-derived cell lines BxPC-3 and PANC-1. Using a dynamic light scattering (DLS) system, we measured the average size and Zeta potential of sEVs. For BxPC-3-derived sEVs, the average size was 114.0 ± 15.1 nm and the Zeta potential was −8.72 mV ([Figure 1](#fig1){ref-type="fig"}A). For HPSC-derived EV, the average size was 90.7 ± 9.6 nm and the Zeta potential was −2.82 mV ([Figure S1](#mmc1){ref-type="supplementary-material"}A). For PANC-1-derived EV, the average size was 132.9 ± 40.0 nm and the Zeta potential was −7.40 mV ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Transmission electron microscopy (TEM) revealed that the diameter of most BxPC-3-derived EVs ranged from 50 to 120 nm ([Figure 1](#fig1){ref-type="fig"}B). The diameter of most HPSC-derived EVs ranged from 50 to 100 nm, and the diameter of most PANC-1-derived EVs ranged from 50 to 150 nm ([Figure S1](#mmc1){ref-type="supplementary-material"}B). The sizes measured by DLS and TEM are consistent with the size of sEVs measured in previous studies using similar technology ([@bib79]). Western blot showed that EVs derived from HPSC, PANC-1, and BxPC-3 expressed CD9, CD63, and HSP70, but not GM130 ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}C). HPSC, PANC-1, and BxPC-3 cells expressed GM130 and HSP70, but not CD9 or CD63 ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}C). These results indicated that the EVs we isolated from supernatant were sEVs.Figure 1The Impact of sEVs on T Lymphocytes(A) DLS system measured the average size of BxPC-3-derived sEVs.(B) TEM image showing the morphology of sEVs (black arrowheads).(C) Western blot assays were used to analyze the expression of sEVs biomarkers.(D) Confocal microscope showing the uptake of tdTomato-labeled sEVs by T lymphocytes. DAPI (blue) pointing the nuclei of T lymphocytes and tdTomato (orange) pointing the sEVs. Three biological replicates were made in each group.(E) Flow cytometry showed the ratio of tdTomato-sEVs-positive T lymphocytes. Data shown are mean ± standard deviation. Three biological replicates were made in each group.(F) Line chart showing the BxPC-3 survival curve. Cell index (y axis) indicating the number of live BxPC-3 cells. The number of live BxPC-3 cells was real-time monitored from the day of cell seeding to co-culture with T lymphocytes. The BxPC-3 survival curve reflected the cytotoxic activity of T lymphocyte. Each point in the graph constituting the curve represented the average of 3 biological replicates. Quantifications of 24, 48, and 72 h were expressed as mean ± SD of 3 biological replicates.(G) ELISA showing the concentration of TGF-β1 secreted in supernatant (n = 3).(H) Line chart showing the BxPC-3 survival curve. The BxPC-3 survival curve reflected the cytotoxic activity of Ctrl-T, lEVs-T, and sEVs-T. The BxPC-3 survival curve reflected the cytotoxic activity of T lymphocyte. Each point in the graph constituting the curve represented the average of 4 biological replicates. Quantifications of 24, 48, and 72 h were expressed as mean ± SD of 4 biological replicates.Data shown are mean ± standard deviation. ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001 (two-tailed, unpaired Student\'s t test).

To trace sEVs, we transfected BxPC-3 cells with a CMV promoter-driven tdTomato-tagged *CD63* gene using a lentivirus vector system and isolated the tdTomato-labeled sEVs. To determine whether PC-derived sEVs are taken up by T lymphocytes, we incubated healthy human peripheral T lymphocytes with PBS (Ctrl-T), unlabeled BxPC-3-derived sEVs (sEVs-T), or tdTomato-labeled BxPC-3-derived sEVs (td-sEVs-T) for 3 days, and visualized the cultured T lymphocytes using confocal microscopy ([Figure 1](#fig1){ref-type="fig"}D). The flow data of td-sEVs uptake was also analyzed ([Figure 1](#fig1){ref-type="fig"}E). The tdTomato fluorescence was observed in td-sEVs-T, indicating that the sEVs were taken up by T lymphocytes.

The key role of T lymphocytes in tumor immunity is cytotoxic activity. We speculated that the cytotoxic activity of T lymphocytes might be affected by tumor cell-derived sEVs. To this aim, we examined the cytotoxic activities of sEVs-T *in vitro* using an RTCA-DP system. After 3 days with or without cell lines-derived sEVs treatment, T lymphocytes were isolated and co-incubated with HPSC, BxPC-3, or PANC-1 cells at a 20:1 ratio. After 48 h of co-culture, BxPC-3 cells cultured with sEVs-T ([Figure 1](#fig1){ref-type="fig"}F, green line) showed a cell index higher than cells cultured with Ctrl-T ([Figure 1](#fig1){ref-type="fig"}F, blue line) and lower than cells cultured without T lymphocytes ([Figure 1](#fig1){ref-type="fig"}F, red line). A similar result was also observed with PANC-1-derived sEVs-treated T lymphocytes, whereas HPSC-derived sEVs had no significant effect on the cytotoxic activity of T lymphocytes ([Figure S1](#mmc1){ref-type="supplementary-material"}D). These results indicated that PC cells-derived sEVs treatment impaired the cytotoxic activity of T lymphocytes, whereas Ctrl-T exhibited significant anti-tumor activity. To compare the effects of sEVs and lEVs on the cytotoxic activity of T lymphocytes, we isolated sEVs and lEVs to treat T lymphocytes, respectively. For PC cell lines (BxPC-3 and PANC-1), the cytotoxic activity of sEVs-T was most impaired and there is no difference in cytotoxic activity between lEVs-T and Ctrl-T ([Figures 1](#fig1){ref-type="fig"}H and [S1](#mmc1){ref-type="supplementary-material"}D). For pancreatic normal cell lines (HPSC), there was no significant difference in cytotoxic activity between Ctrl-T, lEVs-T, and sEVs-T ([Figure S1](#mmc1){ref-type="supplementary-material"}D). These results indicated that sEVs played an important role in the reduction of cytotoxic activity. We also examined the concentration of cytokine transforming growth factor (TGF)-β1, which negatively regulates cytotoxic activity. BxPC-3- and PANC-1-derived sEVs upregulated the secretion of TGF-β1, whereas HPSC-derived sEVs did not ([Figures 1](#fig1){ref-type="fig"}G and [S1](#mmc1){ref-type="supplementary-material"}E).

sEVs Promote Development of T Lymphocytes with Regulatory Phenotype {#sec2.2}
-------------------------------------------------------------------

To explore how PC-derived sEVs affect the cytotoxic activity of T lymphocytes, we tested the immune landscape of BxPC-3-derived sEVs-treated T lymphocytes by CyTOF ([Figure 2](#fig2){ref-type="fig"}A). A total of 42 biomarkers including cell membrane proteins and cytokines were enrolled, and 37 clusters were identified ([Figures 2](#fig2){ref-type="fig"}B and 2C). Ctrl-T heatmap and sEVs-T heatmap were also provided in [Figure S2](#mmc1){ref-type="supplementary-material"}A. We also analyzed the expressions of activation markers (CD3, CD25, CD69, and CD137). As shown in [Figure S2](#mmc1){ref-type="supplementary-material"}B, CD25 and CD137 were expressed more in sEVs-T than that in Ctrl-T. There was no significant difference in CD3 or CD69 expression between Ctrl-T and sEVs-T. These results suggested that cultured T lymphocytes were in an activated state. The immune landscape of sEVs-T was significantly altered compared with that in Ctrl-T, especially in CD25+ T cells, FOXP3+ T cells, PD-1+ T cells, PD-L1+ T cells, CTLA4+ T cells, and Tim-3+ T cells ([Figure 2](#fig2){ref-type="fig"}D). Meanwhile, the immunosuppressive cytokines IL-10 and TGF-β1, which were necessary for Treg induction, were highly expressed in sEVs-T ([Figure 2](#fig2){ref-type="fig"}D). Treg plays a negative role in antitumor immunity. The membrane protein CD25 and the transcription factor FOXP3 are critical biomarkers of Treg. Treg induction requires prior stimulation such as TGF-β1, IL-10, and IL-2, and the induced Treg expresses high levels of co-stimulator CTLA-4, PD-L1, and PD-1 ([@bib53]). PD-1 and PD-L1 are both expressed on Treg, and blocking the interaction of PD-1 with PD-L1 affects the suppression level of Treg ([@bib5]). CTLA-4 is expressed constitutively on CD4+CD25+ FOXP3+ Tregs and plays an essential role in maintaining the function of Tregs ([@bib84]; [@bib69]). As an immune checkpoint protein, Tim-3 is also expressed on FOXP3+ Tregs and is involved in enhancing the regulatory function of Tregs ([@bib72]). Given that, we focus on the induction of Treg by sEVs. According to the high expression of CD4, CD25, and FOXP3, we identified the Treg cluster in cluster 7--10 ([Figure 2](#fig2){ref-type="fig"}C) and further marked the Treg range of tSNE (tSNE is a nonlinear dimensionality reduction algorithm, which is suitable for dimensionality reduction of high-dimensional flowdata to two dimensions for visualization) in [Figure 3](#fig3){ref-type="fig"}A. Moreover, the immunosuppressive biomarkers PD-1, PD-L1, CTLA4, Tim-3, IL-10, and TGF-β1 were also enriched in cluster 7--10 ([Figure 3](#fig3){ref-type="fig"}A). We then analyzed the correlation between these immunosuppressive molecules and CD25 and found that the expression of CD25 was positively correlated with the expressions of FOXP3, PD-1, PD-L1, CTLA4, Tim-3, IL-10, and TGF-β1 ([Figure 3](#fig3){ref-type="fig"}B). FOXP3 also showed a positive correlation with PD-1, CTLA4, Tim-3, IL-10, and TGF-β1, but not with PD-L1 ([Figure 3](#fig3){ref-type="fig"}C). We also examined the correlations between these immunosuppressive molecules and the abundance of tumor-infiltrating Tregs in PC tissue from the tumor-immune system interactions database (TISIDB) (<http://cis.hku.hk/TISIDB/>). Positive correlations were identified between Treg abundance and PD-1 (R = 0.504, p \< 0.001), PD-L1 (R = 0.488, p \< 0.001), CTLA4 (R = 0.627, p \< 0.001), Tim-3 (R = 0.872, p \< 0.001), IL-10 (R = 0.607, p \< 0.001), and TGF-β1 (R = 0.325, p \< 0.001) ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Therefore, we speculated that PC-derived sEVs mainly upregulate Treg expression.Figure 2Immune Landscape of BxPC-3-Derived sEVs-Treated T Lymphocytes(A) tSNE plot showing the differences in distributions of the Ctrl-T and sEVs-T.(B) tSNE plot showing a total of 37 clusters and the distributions in clusters of the Ctrl-T and sEVs-T.(C) Heatmap showing the differential expressions of 42 immune markers in the 37 cell clusters. The label on the left showing the T cell types of clusters according to typically expressed markers.(D) Heatmap (top) showing the differential expressions of 42 immune markers between Ctrl-T and sEVs-T (n = 5). Box plot (bottom) showing the differential expressions of 8 immunosuppressive biomarkers between Ctrl-T and sEVs-T (n = 5). Data derived from CyTOF. Data shown are mean ± standard deviation. ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001 (two-tailed, unpaired Student\'s t test).Figure 3The Expressions of Immunosuppressive Biomarkers(A) tSNE plots (top) showing the identification of CD4+ CD25+ FOXP3+ Treg clusters. tSNE plots (bottom) showing the differences of immunosuppressive biomarkers expressed in Treg clusters.(B) Scatterplots showing the correlation between immunosuppressive biomarkers and CD25 (n = 10). R value meaning correlation coefficient, p \< 0.05 meaning statistically significant (Pearson\'s correlation).(C) Scatterplots showing the correlation between immunosuppressive biomarkers and FOXP3 (n = 10). R value meaning correlation coefficient, p \< 0.05 meaning statistically significant (Pearson\'s correlation).

To examine this possibility, we incubated healthy human peripheral T lymphocytes with BxPC-3-derived sEVs *in vitro*. The regulatory phenotype in cultured T lymphocytes was evaluated by intracellular expression of FOXP3 in CD4+CD25+ T lymphocytes using flow cytometry. We performed a titration dose as 1, 5, 10, 20, 50, and 100 μg/mL of BxPC-3-derived sEVs to stimulate T lymphocytes. As shown in [Figure 4](#fig4){ref-type="fig"}A, the proportion of FOXP3+ Treg cells was the highest in 100 μg/mL BxPC-3-sEVs-treated group, compared with other lower-dose groups. We also detected FOXP3+ Treg proportion at different times during sEVs treatment. The proportion of FOXP3+ Tregs in sEVs-T was substantially increased between 1 and 3 days compared with Ctrl-T ([Figure 4](#fig4){ref-type="fig"}B). The enhancement in the proportion of FOXP3+ Treg was time dependent, and the largest enhancement was detected after a 3-day stimulation ([Figure 4](#fig4){ref-type="fig"}B). This result was also exhibited in PANC-1-derived sEVs-treated T lymphocytes ([Figure S3](#mmc1){ref-type="supplementary-material"}B). However, there was no significant difference in Treg induction during HPSC-derived sEVs treatment ([Figure S3](#mmc1){ref-type="supplementary-material"}C). We compared the induction of Treg by sEVs from HPSC, PANC-1, and BxPC-3 and found that the proportion of FOXP3+ Treg cells was the highest in BxPC-3-sEVs-T compared with PANC-1-sEVs-T, HPSC-sEVs-T, and Ctrl-T ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Western blot results were consistent with these findings ([Figure S3](#mmc1){ref-type="supplementary-material"}E). We also treated T lymphocytes with BxPC-3-derived lEVs (lEVs-T), sEVs (sEVs-T), and supernatant lyophilized powders (Sup-T) at a protein concentration 100 μg/mL, or treated with isovolumetric PBS (Ctrl-T). The highest proportion of FOXP3+ Treg was in sEVs-T ([Figures 4](#fig4){ref-type="fig"}C and 4D). Also, there is no significant difference in the proportion of FOXP3+ Treg among the Ctrl-T, Sup-T, and lEVs-T ([Figures 4](#fig4){ref-type="fig"}C and 4D). These results indicated that treatment with 100 μg/mL BxPC-3-derived sEVs for 3 days was more effective in inducing Tregs. We thus chose T cells stimulated by BxPC-3-derived sEVs for 3 days for subsequent experiments.Figure 4BxPC-3-Derived sEVs Induce Treg Expansion(A) Flow cytometry showing the FOXP3 expression at titration dose of BxPC-3-derived sEVs treatment (n = 3). Fold changes are relative to control.(B) Flow cytometry showing the FOXP3 expression at different time after BxPC-3-derived sEVs stimulation (n = 3). Fold changes are relative to control.(C) Flow cytometry showing the FOXP3 expression during treatment with 100 μg/mL BxPC-3-derived supernatant, lEVs, and sEVs (n = 3).(D) Western blots showing the FOXP3 expression during treatment with 100 μg/mL BxPC-3-derived supernatant, lEVs, and sEVs (n = 3).The graphs are from a single experiment, which is representative of three independent experiments. Data shown are mean ± standard deviation. ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001; "ns" meaning "no significant difference" (two-tailed, unpaired Student\'s t test).

RNA-Seq and GSEA Identify Alterations in Metabolism and DDR Pathways in sEVs-T {#sec2.3}
------------------------------------------------------------------------------

To gain insight into the molecular mechanism by which sEVs upregulate the proportion of FOXP3+ Tregs in T lymphocytes, we performed GSEA based on our previous RNA-seq data in GEO database ([GSE115831](ncbi-geo:GSE115831){#intref0015}). p value \<0.05 and q value \<0.25 mean statistically significant. Top gene sets enriched in sEVs-T were listed in [Table 1](#tbl1){ref-type="table"}. Among these gene sets, TGF-β signaling gene set attracted our attention. TGF-β1-SMAD2/3 was a typical pathway in inducing Treg. This gene set was enriched in sEVs-T ([Figure S4](#mmc1){ref-type="supplementary-material"}A). We detected the TGF-β1 concentration in re-suspended Sup, lEVs, and sEVs using ELISA method. We found that the content of TGF-β1 in sEVs was higher than that in Sup and lEVs ([Figure S4](#mmc1){ref-type="supplementary-material"}B). To further determine whether TGF-β1 was contained in sEVs, we extracted proteins of BxPC-3 and BxPC-3-derived sEVs and performed western blot to detect the expression of TGF-β1. As shown in [Figure S4](#mmc1){ref-type="supplementary-material"}C, TGF-β1 was detected in both BxPC-3 and BxPC-3-derived sEVs. To track the process of BxPC-3-derived sEVs transporting TGF-β1 from BxPC-3 cells to T cells, we transfected tdTomato-CD63-BxPC-3 cells with a CMV promoter-driven EGFP-tagged TGF-β1 gene using a lentivirus vector system (TGF-β1/CD63-BxPC-3). tdTomato-CD63-BxPC-3 cells transfected with EGFP gene were considered as control (Ctrl/CD63-BxPC-3). We then extracted the TGF-β1/CD63-BxPC-3-derived sEVs (TGF-β1/CD63-sEVs) and Ctrl/CD63-BxPC-3-derived sEVs (Ctrl/CD63-sEVs) to stimulate the peripheral T cells. Green fluorescence was expressed more in TGF-β1/CD63-sEVs-T than that in Ctrl/CD63-sEVs-T ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Flow cytometry further determined that EGFP fluorescence was detected in TGF-β1/CD63-sEVs-T but not in Ctrl/CD63-sEVs-T ([Figure S4](#mmc1){ref-type="supplementary-material"}E). These results indicated that TGF-β1 was carried by sEVs from BxPC-3 to T cells. To determine the specificity of sEVs-derived TGF-β1 for Treg induction, TGF-β1 inhibitor Disitertide (50μg/mL) was premixed with sEVs to competitively inhibit sEVs-derived TGF-β1. As shown in [Figure S4](#mmc1){ref-type="supplementary-material"}F, compared with sEVs-T, Disitertide reduced the induction of Tregs by sEVs. However, the proportion of FOXP3+ Treg was still higher in D+ sEVs-T than that in Ctrl-T. Despite the use of Disitertide, the induction of FOXP3+ Treg by sEVs was not completely suppressed. These results indicated that there existed other molecular mechanisms that were involved in inducing Treg.Table 1Top Gene Sets Enriched in sEVs-TGene Sets NameNESNom p ValueFDR q ValueTNF-α signaling via NF-κB2.67500Inflammatory response2.3800p53 pathway2.25300IL-6 JAK STAT3 signaling2.24700Hypoxia2.24500UV response UP2.19900KRAS signaling UP2.14700Estrogen response late2.12600Apoptosis2.12600Epithelial mesenchymal transition2.10300Xenobiotic metabolism2.06900Estrogen response early1.99200Coagulation1.93500Apical junction1.92800Interferon gamma response1.92600Myogenesis1.86400.001Glycolysis1.86100.001IL-2 STAT5 signaling1.85800.001Allograft rejection1.84900.001TGF-β signaling1.8460.0010.001Heme metabolism1.83800.001Interferon alpha response1.83300.001KRAS signaling DN1.8200.001Unfolded protein response1.81200.001Spermatogenesis1.750.0030.002UV response DN1.74700.002Complement1.70200.003Angiogenesis1.6990.0110.003Reactive oxygen species pathway1.690.0060.003Notch signaling1.6740.0060.004Myc targets V11.5640.0030.016DNA repair1.4450.0210.047Adipogenesis1.4220.0250.057Oxidative phosphorylation1.3760.030.081mTORC1 signaling1.3750.0420.079[^3][^4]

In addition, we also wanted to find other molecular mechanisms that may be involved in inducing Treg. Metabolic programs are critical regulators of immune responses ([@bib56]). Changes in cellular metabolism or host metabolic environment can affect the function and differentiation of immune cells, for example, to promote or inhibit Treg differentiation ([@bib88]; [@bib60]). As shown in [Figure 5](#fig5){ref-type="fig"}A, GSEA revealed that BxPC-3-derived sEVs showed altered expressions of genes involved in the Glycolysis gene set and Oxidative Phosphorylation gene set, which are related with metabolism. KEGG pathway analysis listed more specific metabolism-related pathways ([Figure 5](#fig5){ref-type="fig"}B). AMPK is an important regulator of cellular metabolism that shuts down the synthetic pathway of energy demand but promotes the mechanism of energy production ([@bib68]). Given that both Glycolysis and Oxidative Phosphorylation gene sets were enriched in sEVs-T, we examined the activation of AMPK and the expression of Sirtuins (SIRTs), which also function as energy sensors in metabolism. As shown in [Figure S5](#mmc1){ref-type="supplementary-material"}A, SIRT1, SIRT2, and SIRT6 mRNA were expressed more in sEVs-T, compared with Ctrl-T. Also, there was no significant difference in the expression of SIRT3, SIRT4, SIRT5, or SIRT7 mRNA between Ctrl-T and sEVs-T. The levels of phosphorylated AMPK and the protein expressions of SIRT1/SIRT2/SIRT6 were all increased in sEVs-T compared with Ctrl-T ([Figure 5](#fig5){ref-type="fig"}C). To determine whether AMPK and SIRT1/2/6 play an important role in reducing the cytotoxic activity of sEVs-T, we used selective inhibitors to suppress the phosphorylation of AMPK (20 μM Compound C, [Figure S5](#mmc1){ref-type="supplementary-material"}B) and inhibit the expressions of SIRT1 (10 μM EX-527, [Figure S5](#mmc1){ref-type="supplementary-material"}C), SIRT2 (40 μM AGK2, [Figure S5](#mmc1){ref-type="supplementary-material"}D), and SIRT6 (100 μM OSS_128167, [Figure S5](#mmc1){ref-type="supplementary-material"}E), and then detected the cytotoxic activity of inhibitors-treated sEVs-T. As shown in [Figure 5](#fig5){ref-type="fig"}D, although the cytotoxic activity of sEVs-T was impaired, it was restored when treated with SIRT1/2/6 inhibitors. These results suggested that sEVs reduced the cytotoxic activity of T lymphocytes by upregulating AMPK phosphorylation and SIRT1/2/6 expressions.Figure 5Metabolism and DDR Pathway Alterations in sEVs-T(A, B, and E) GSEA was conducted to search gene sets and KEGG pathways altered by sEVs stimulation. (A) GSEA showing the alteration of gene sets involved in metabolism in sEVs-T. p value \<0.05 and q value \<0.25 meaning statistically significant. (B) GSEA showing the alteration of KEGG pathways involved in metabolism in sEVs-T. p value \<0.05 and q value \<0.25 meaning statistically significant. The ratio of count meaning altered gene/total gene of pathway. (E) GSEA showing the alteration of gene sets involved in DNA damage response in sEVs-T.(C) Western blot showing the upregulation of metabolic regulator p-AMPK, SIRT1, SIRT2, and SIRT6 in sEVs-T (n = 3). Data shown are mean ± standard deviation. ∗p \< 0.05; ∗∗p \< 0.01 (two-tailed, unpaired Student\'s t test).(D) Line chart reflecting the cytotoxic activity of T lymphocyte through BxPC-3 survival curve. sEVs down regulated the cytotoxic activity of T lymphocytes, and it was rescued by AMPK inhibitor Compound C (CC), SIRT1 inhibitor EX527, SIRT2 inhibitor AGK2, and SIRT6 inhibitor OSS_128167 (OSS). Each point in the graph constituting the curve represented the average of 4 biological replicates.(F) Immunofluorescence showing the increased foci of γ-H2AX, RAD51, RPA2, and 53BP1 in sEVs-T (n = 3). Data shown are mean ± standard deviation. ∗p \< 0.05; ∗∗p \< 0.01 (two-tailed, unpaired Student\'s t test).(G) Western blot showing the upregulated activation of DDR sensor p-ATM in sEVs-T. The ratio of phosphor-ATM/ATM meaning the degree of ATM activation (n = 3). Data shown are mean ± standard deviation. ∗p \< 0.05 (two-tailed, unpaired Student\'s t test).(H) Line chart reflecting the cytotoxic activity of T lymphocyte through BxPC-3 survival curve. sEVs down-regulated the cytotoxic activity of T lymphocytes, and it was rescued by ATM inhibitor KU-60019. Each point in the graph constituting the curve represented the average of 4 biological replicates.Graphs of western blots and immunofluorescence are from a single experiment, which is representative of three independent experiments.

Previous studies have shown that induction of Treg cells is provoked by UV-induced DNA damage and repair ([@bib74]; [@bib4]; [@bib54]). In addition to metabolism-related gene sets, DDR-related gene sets of DNA repair and UV response Up were also enriched in sEVs-T ([Figure 5](#fig5){ref-type="fig"}E). To examine the DDR in sEVs-T, we performed immunofluorescence for γ-H2AX, RAD51, RPA2, and 53BP1, which are protein markers of DDR. As shown in [Figure 5](#fig5){ref-type="fig"}F, the γ-H2AX, RAD51, RPA2, and 53BP1 foci were significantly increased in sEVs-T compared with Ctrl-T. It suggested that DDR was induced in sEVs-treated T lymphocytes. The ATM kinase is a critical sensor for the DDR and mediates the DDR-induced AMPK ([@bib1]; [@bib71]). Western blot showed that the level of phosphorylated ATM was significantly increased in sEVs-T compared with Ctrl-T ([Figure 5](#fig5){ref-type="fig"}G). To determine whether the activation of ATM was due to the excessive use of sEVs, we performed a titration dose as 20, 50, and 100 μg/mL sEVs treatment and detected the phosphorylation of ATM. As shown in [Figure S5](#mmc1){ref-type="supplementary-material"}G, the phosphorylation of ATM was dose dependent and the highest phosphorylation was detected in 100 μg/mL sEVs stimulation. Previous study has reported that the exosomes used to stimulate T cells is 100--200 μg/mL protein ([@bib92]). This result indicates that DNA damage induction is not due to excessive sEVs used. To test whether sEVs-induced ATM activation was involved in impairing the cytotoxic activity of sEVs-T, we used the ATM inhibitor KU60019 and tested the cytotoxic activity of cultured T lymphocytes using the RTCA-DP system. We confirmed that the phosphorylation of ATM in sEVs-T was suppressed by 50 μM KU60019 ([Figure S5](#mmc1){ref-type="supplementary-material"}F). As shown in [Figure 5](#fig5){ref-type="fig"}H, although the cytotoxic activity of sEVs-T was impaired, it was restored when treated with 50 μM KU60019 (sEVs + KU-T).

These results indicated that the metabolism and DDR pathways were altered in sEVs-induced T cells and that these sensor molecules ATM, AMPK, and SIRT1/2/6 play an important role in sEVs-induced cytotoxic activity reduction.

sEVs-Induced ATM-AMPK-SIRT1/2/6 Is Essential for Upregulated Expression of FOXP3 {#sec2.4}
--------------------------------------------------------------------------------

In T cells, ATM coordinates DNA double-strand breaks (DSB) and plays roles at several stages of T cell development ([@bib55]). Metabolic programs are also essential for the control of Treg and Teff development in inflammatory diseases ([@bib59]). We hypothesized that the activation of ATM and AMPK and the upregulated expression of SIRT1, SIRT2, and SIRT6 might be linked to the transcriptional upregulation of FOXP3 in sEVs-treated T cells. To determine whether ATM, AMPK, and SIRT1/2/6 act in sequence to upregulate FOXP3 expression, we used selective inhibitors to suppress the phosphorylation of ATM and AMPK and inhibit the expressions of SIRT1, SIRT2 and SIRT6. We found that sEVs-T exhibited significantly enhanced phosphorylation of ATM ([Figure 6](#fig6){ref-type="fig"}A) and AMPK ([Figure 6](#fig6){ref-type="fig"}B) and upregulated expressions of SIRT1 ([Figure 6](#fig6){ref-type="fig"}C), SIRT2 ([Figure 6](#fig6){ref-type="fig"}D), and SIRT6 ([Figure 6](#fig6){ref-type="fig"}E). Treatment of sEVs-T with the ATM kinase inhibitor KU60019 reduced AMPK phosphorylation and SIRT1/2/6 expression ([Figure 6](#fig6){ref-type="fig"}A). Treatment of sEVs-T with the AMPK inhibitor Compound C diminished sEVs-induced expressions of SIRT1/2/6 but did not affect ATM phosphorylation ([Figure 6](#fig6){ref-type="fig"}B). In contrast, the SIRT1 inhibitor EX-527, SIRT2 inhibitor AGK2, and SIRT6 inhibitor OSS_128167 had no effect on basal or sEVs-induced ATM or AMPK phosphorylation ([Figures 6](#fig6){ref-type="fig"}C--6E). We also did not observe interference between SIRT1, SIRT2, and SIRT6 ([Figures 6](#fig6){ref-type="fig"}C--6E). Notably, reducing the phosphorylation of ATM and AMPK and down-regulation of the expression of SIRT1, SIRT2, and SIRT6 prevented sEVs-upregulated expression of FOXP3 ([Figures 6](#fig6){ref-type="fig"}A--6E). A similar result was observed in examining CD4+CD25^high^FOXP3+ cells using flow cytometry ([Figure 6](#fig6){ref-type="fig"}F), which further indicated that ATM, AMPK, SIRT1, SIRT2, and SIRT6 are essential for the development of sEVs-induced Treg. These data suggested that sEVs-upregulated FOXP3 is dependent on the ATM-AMPK-SIRT1/SIRT2/SIRT6 axis.Figure 6sEVs-Upregulated FOXP3 Is Dependent on the ATM-AMPK-SIRT1/SIRT2/SIRT6 Axis(A) Peripheral T lymphocytes derived from three healthy humans were treated with DMSO, 50 μM KU60019, BxPC-3-derived sEVs, and sEVs combined with 50 μM KU60019, respectively.(B) Peripheral T lymphocytes derived from three healthy humans were treated with DMSO, 20 μM Compound C, BxPC-3-derived sEVs, and sEVs combined with 20 μM Compound C, respectively.(C) Peripheral T lymphocytes derived from three healthy humans were treated with DMSO, 10 μM EX-527, BxPC-3-derived sEVs, and sEVs combined with 10 μM EX-527, respectively.(D) Peripheral T lymphocytes derived from three healthy humans were treated with DMSO, 40 μM AGK2, BxPC-3-derived sEVs, and sEVs combined with 40 μM AGK2, respectively.(E) Peripheral T lymphocytes derived from three healthy humans were treated with DMSO, 100 μM OSS_128167, BxPC-3-derived sEVs, and sEVs combined with 100 μM OSS_128167, respectively.(F) T lymphocytes were from the same source as (A--E). Flow cytometry showing the FOXP3 expression.(A--F) Data shown are mean ± standard deviation. n = 3. ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001; NS, no significant difference (two-tailed, unpaired Student\'s t test).Graphs of western blots and flow cytometry are from a single experiment, which is representative of three independent experiments.

sEVs-Upregulated FOXP3 Is Mediated by the Nuclear Translocations of FOXO1A and FOXO3A {#sec2.5}
-------------------------------------------------------------------------------------

Previous studies showed that the FOXO1A and FOXO3A transcription factors directly regulate Foxp3 gene transcription through Foxo-binding sites in Foxp3 loci ([@bib63]), promote the transcription of FOXP3 gene in induced Tregs, and control Treg development and function ([@bib39]). FOXO1A and FOXO3A are also involved in DNA repair, cellular metabolism, and specific lymphocyte function ([@bib32]; [@bib19]). We thus hypothesized that FOXO1A and FOXO3A may be involved in sEVs-upregulated expression of FOXP3. We examined the expressions of FOXO1A and FOXO3A in T lymphocytes with or without sEVs treatment and found that both FOXO1A and FOXO3A were expressed at higher levels in sEVs-T than in Ctrl-T ([Figure 7](#fig7){ref-type="fig"}A). In addition, sEVs-mediated induction of FOXO1A was prevented by selective inhibitors targeting ATM, AMPK, SIRT1, and SIRT6, whereas sEVs-mediated upregulation of FOXO3A was reduced by inhibitors targeting ATM, AMPK, SIRT1, SIRT2, and SIRT6 ([Figure 7](#fig7){ref-type="fig"}B). This result indicated that ATM, AMPK, and SIRT1/2/6 might act as upstream regulators of FOXO1A and/or FOXO3A, which subsequently regulate FOXP3 expression.Figure 7sEVs-Induced Nuclear Translocations of FOXO1A and FOXO3A Upregulated the Expression of FOXP3(A) Western blot showing the upregulation of FOXO1A and FOXO3A in sEVs-T (n = 3).(B) Western blot showing the expressions of FOXO1A and FOXO3A in T lymphocytes during different treatment as ([Figures 6](#fig6){ref-type="fig"}A--6E) (n = 3).(C) Western blot showing the expressions of FOXO1A, FOXO3A, and FOXP3 in subcellular fractions of treated T lymphocytes. T lymphocytes were from the same source as (A) (n = 3).(A--C) Data shown are mean ± standard deviation. n = 3. ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001; NS, no significant difference (two-tailed, unpaired Student\'s t test).Graphs of western blots are from a single experiment, which is representative of three independent experiments.

To investigate the role of FOXO1A and FOXO3A in the regulation of FOXP3, we performed nuclear and cytoplasmic extraction and western blot. FOXO1A was significantly upregulated in sEVs-T compared with Ctrl-T and redistributed from the cytoplasm to the nucleus, along with the upregulated FOXP3 ([Figure 7](#fig7){ref-type="fig"}C). Treatment with the ATM kinase inhibitor KU60019 not only reduced the expression of FOXO1A but also reversed the redistribution of FOXO1A and weakened the expression of FOXP3 ([Figure 7](#fig7){ref-type="fig"}C). The sEVs-induced redistribution and KU60019-induced reversed redistribution of FOXO3A were similar to results with FOXO1A ([Figure 7](#fig7){ref-type="fig"}C).

We next used structured illumination microscopy (SIM) to capture the intracellular distribution of FOXO1A and FOXO3A and the expression of FOXP3 during sEVs treatment with or without ATM inhibitor. The three-dimensional (3D) images were visualized and analyzed by Imaris software. The intracellular distribution of FOXO1A and FOXO3A under SIM ([Figures 8](#fig8){ref-type="fig"}A and 8C) were consistent with the western blot results ([Figure 7](#fig7){ref-type="fig"}C). In Ctrl-T, FOXO1A and FOXO3A were scattered in the cytoplasm and nucleus; in sEVs-T, FOXO1A and FOXO3A were mainly distributed in the nucleus; and in KU60019-treated sEVs-T (sEVs + KU-T), FOXO1A and FOXO3A were scattered again into the cytoplasm ([Figures 8](#fig8){ref-type="fig"}A and 8C). The mean fluorescence intensity of nuclear FOXO1A/FOXO3A was calculated from the colocalization of total and nuclear FOXO1A/FOXO3A. The ratio of nuclear/total FOXO1A in sEVs-T was higher than that in Ctrl-T and was diminished by KU60019 ([Figure 8](#fig8){ref-type="fig"}B). The pattern of nuclear/total FOXO3A in Ctrl-T, KU60019-treated Ctrl-T, sEVs-T, and sEVs + KU-T was similar to results with FOXO1A ([Figure 8](#fig8){ref-type="fig"}D). The expression of FOXP3 was highest in sEVs-T and reduced in sEVs + KU-T ([Figures 8](#fig8){ref-type="fig"}B and 8D), which was consistent with the western blot results ([Figure 7](#fig7){ref-type="fig"}C). Moreover, the intracellular distribution of FOXP3 was similar to that of FOXO1A and FOXO3A during sEVs treatment with or without KU60019. These data suggested that sEVs-upregulated FOXP3 was associated with not only the upregulated expressions but also the nuclear translocations of FOXO1A and FOXO3A.Figure 8Translocations of FOXO1A and FOXO3A in Subcellular Fractions under the Sight of SIM(A) Reconstructed 3D images showing the FOXO1A translocation (red meaning total expression, yellow meaning nuclei expression) and FOXP3 (green) expression in treated T lymphocytes. T lymphocytes were from the same source as [Figure 6](#fig6){ref-type="fig"}A. Scale bar is indicated in image.(B) Ratio of Nuclear/Total expression of FOXO1A and mean fluorescence intensity (MFI) of FOXP3 from Imaris analysis as in (A) (n = 3).(C) Reconstructed 3D images showing the FOXO3A translocation (red meaning total expression, yellow meaning nuclei expression) and FOXP3 (green) expression in treated T lymphocytes. T lymphocytes were from the same source as ([Figure 6](#fig6){ref-type="fig"}A). Scale bar indicated in image.(D) Ratio of Nuclear/Total expression of FOXO3A and mean fluorescence intensity (MFI) of FOXP3 from Imaris analysis as in (C) (n = 3).(B and D) Data shown are mean ± SD. n = 3. ∗p \< 0.05; ∗∗p \< 0.01 and ∗∗∗∗p \< 0.0001 (two-tailed, unpaired Student\'s t test).Images are from a single experiment, which is representative of three independent experiments.

We also used inhibitors Compound C, EX-527, AGK2, and OSS_128167 to treat T lymphocytes and analyzed the intracellular distribution of FOXO1A and FOXO3A and the expression of FOXP3 using SIM and Imaris software. The ratio of nuclear/total FOXO1A in sEVs-T was higher than that in Ctrl-T and was diminished by Compound C, EX-527, and OSS_128167 ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). The ratio of nuclear/total FOXO3A in sEVs-T was higher than that in Ctrl-T and was diminished by Compound C, EX-527, AGK2, and OSS_128167 ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D). The expression of FOXP3 was highest in sEVs-T and reduced by Compound C, EX-527, AGK2, and OSS_128167 ([Figures 8](#fig8){ref-type="fig"}B and 8D). These results indicated that SIRT1 and SIRT6 mediated the nuclear translocations of FOXO1A and FOXO3A, whereas SIRT2 mediated the nuclear translocation of FOXO3A, but not FOXO1A.

In general, ATM/AMPK/SIRTs-mediated nuclear translocations of FOXO1A and FOXO3A play an important role in sEVs-upregulated FOXP3.

FOXO1A, FOXO3A, and FOXP3 Are Highly Expressed in PDAC-Metastatic Lymph Nodes {#sec2.6}
-----------------------------------------------------------------------------

We identified the upregulated FOXO1A, FOXO3A, and FOXP3 in sEVs-T *in vitro*. Whether the expressions of FOXO1A and FOXO3A were related to Treg in PC tissue? To this aim, we examined the correlations between the abundance of tumor-infiltrating Tregs and the expressions of FOXO1A and FOXO3A in PC tissue from the TISIDB (<http://cis.hku.hk/TISIDB/>). Positive correlations were identified between Treg abundance and the expressions of FOXO1A and FOXO3A ([Figure 9](#fig9){ref-type="fig"}A). We also performed immunohistochemical analysis of 20 pairs of normal and tumor specimens collected from 20 patients with PDAC in our hospital. However, there were only a few FOXO1A-positive cells in the stroma of tumor tissues and almost no positive cells in pancreatic normal tissues ([Figure S7](#mmc1){ref-type="supplementary-material"}A). FOXO3A was highly expressed in pancreatic ductal cells, acinar cells, and stromal cells, and this high expression was observed in both pancreatic normal tissues and tumor tissues ([Figure S7](#mmc1){ref-type="supplementary-material"}B). FOXP3 expression was similar to FOXO1A ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Due to the low expressions of FOXO1A and FOXP3, and the excessive background staining of FOXO3A, we were not available to quantitatively analyze the immunohistochemical results. Compared with the single-cell sequencing results in TISIDB, the sensitivity of our immunohistochemical results was obviously insufficient. We then checked the mRNA expressions of FOXO1A, FOXO3A, and FOXP3 in pancreas and lymph nodes in Gene Database (<https://www.ncbi.nlm.nih.gov/gene/>). We found that FOXO1A and FOXP3 had low expressed in pancreatic tissues and high expressed in lymph node tissue, and that FOXO3A was highly expressed in both pancreatic tissues and lymph nodes. These results suggested that compared with pancreatic tissues, lymph node tissues were more suitable for immunohistochemical analysis of FOXO1A, FOXO3A, or FOXP3 expression. Moreover, the expressions of FOXO1A, FOXO3A, and FOXP3 in PC lymph nodes were still unknown. To this aim, we performed immunohistochemical analysis of 20 pairs of normal and metastatic lymph node specimens. We found that, among these samples, the positive expression rate of FOXO1A in metastatic lymph nodes was 0.72 ± 0.13, which is higher than that in normal lymph node (0.58 ± 0.10) ([Figures 9](#fig9){ref-type="fig"}B and 9C); the positive expression rate of FOXO3A in metastatic lymph nodes was 0.78 ± 0.12, which is higher than that in normal lymph node (0.64 ± 0.12) ([Figures 9](#fig9){ref-type="fig"}D and 9E); and the positive expression rate of FOXP3 in metastatic lymph nodes was 0.59 ± 0.06, which is higher than that in normal lymph node (0.52 ± 0.05) ([Figures 9](#fig9){ref-type="fig"}F and 9G). We further analyzed the correlations between the expression of FOXP3 and the expressions of FOXO1A and FOXO3A in paired lymph nodes. Interestingly, FOXP3 has a positive correlation with the expression of FOXO1A or FOXO3 ([Figure 9](#fig9){ref-type="fig"}H).Figure 9The Expressions of FOXO1A, FOXO3A, and FOXP3 in PDAC Lymph Node(A) Left scatterplots showing the correlation between FOXO1A and Treg abundance. Right scatterplots showing the correlation between FOXO3A and Treg abundance. Data derived from the TISIDB (<http://cis.hku.hk/TISIDB/>).(B) Immunohistochemistry (IHC) images showing the FOXO1A expression in normal and metastatic lymph nodes. Arrowhead indicating the positive expression. Scale bar indicated in image.(C) Quantification of (B) showing the average IHC score of FOXO1A in 20 paired normal and metastatic lymph nodes under 40× objective.(D) Immunohistochemistry images showing the FOXO3A expression in normal and metastatic lymph nodes. Arrowhead indicating the positive expression. Scale bar indicated in image.(E) Quantification of (D) showing the average IHC score of FOXO3A in 20 paired normal and metastatic lymph nodes under 40× objective.(F) Immunohistochemistry images showing the FOXP3 expression in normal and metastatic lymph nodes. Arrowhead indicating the positive expression. Scale bar indicated in image.(G) Quantification of (F) showing the average IHC score of FOXP3 in 20 paired normal and metastatic lymph nodes under 40× objective.(H) Left scatterplots showing the correlation between FOXO1A and FOXP3. Right scatterplots showing the correlation between FOXO3A and FOXP3. Data derived from (A, C, and E).(A) R value meaning correlation coefficient, p \< 0.05 meaning statistically significant (Spearman\'s correlation). (C, E, and G) Data shown are mean ± SD. ∗∗p \< 0.01; ∗∗∗p \< 0.001; ∗∗∗∗p \< 0.0001 (n = 20, paired t test). (H) R value meaning correlation coefficient (n = 40, including 20 normal lymph nodes and 20 metastatic lymph nodes), p \< 0.05 meaning statistically significant (Pearson\'s correlation).

Discussion {#sec3}
==========

Previous studies refer to the EVs with a diameter of 50--150 nm isolated from 100,000 × g as exosomes and EVs with a diameter \>150 nm (or \>200 nm) isolated from 10,000 × g as microvesicles. In our study, we refer to the EVs from the 100,000×*g* pellet of size \<200 nm as sEVs and EVs from the 10,000×*g* pellet of size \>200 nm as lEVs. For respect for previous studies and the readability of previous reports, we still use the term "exosomes" when discussing previous studies, and use the term "sEVs" when discussing our study.

Despite recent advances in effective immunotherapy against solid tumors such as melanoma and non-small cell lung cancer, immunotherapy of PC is less effective and PC shows a high mortality rate, which is attributed to the lack of immunogenicity and the presence of an immunosuppressive microenvironment ([@bib41]). Growing evidence has shown that the T cell population that infiltrates into the microenvironment of PC is primarily Tregs rather than activated anti-tumor T cells ([@bib15]). A high proportion of Tregs in PC tissue is a marker of poor prognosis ([@bib33]). Previous studies have found that tumor cells may shape immune cells into Treg phenotype through metabolic competition and secretion of anti-inflammatory cytokines such as TGF-β1 and IL-10 ([@bib7]; [@bib80]; [@bib97]). Cancer-derived exosomes have been shown to promote Treg expansion, induce TGF-β1 production, and enhance the suppressor activity of Tregs ([@bib81]). In this study, we explored the changes in phenotype and function as well as the corresponding signaling pathways underlying these changes in T lymphocytes after uptake of BxPC-3-derived sEVs.

Exosomes are produced and released by normal tissue cells as well as tumor cells ([@bib23]). However, tumor cell-derived and normal tissue cell-derived exosomes show distinct properties ([@bib52]). In previous studies examining exosomes obtained from serum, urine, or effusions of patients with cancer, the origin was uncertain, as these exosomes may be derived from normal or/and tumor cells. To specifically examine the effects of sEVs on T lymphocytes, here we purified and identified sEVs from BxPC-3 cell culture supernatants and cultured them with isolated healthy peripheral T lymphocytes, as shown in previous studies ([@bib92]; [@bib86]). Some studies demonstrated that the increased Treg population and suppressor function in peripheral blood and tumor tissue of patients with cancer were associated with cancer progression and shorter survival ([@bib94]; [@bib18]; [@bib95]; [@bib73]; [@bib24]; [@bib13]). Early studies indicated that PC induces Tregs by recruitment of myeloid-derived suppressor cells and mast cells, secreting TGF-β1, and metabolic competition ([@bib64]). In our study, the proportion of Tregs, represented by CD4+CD25^high^FOXP3+, was increased after BxPC-3-derived sEVs treatment, and the cytotoxic activity of sEVs-treated T lymphocytes was reduced. Our finding and results from others ([@bib90]; [@bib70]) describe a potential mechanism for Treg enrichment in the tumor tissue of patients with PC. We also found TGF-β1 was carried by sEVs from PC cells to T lymphocytes. However, the induction of Treg by sEVs has not been completely suppressed when sEVs-derived TGF-β1 was blocked. It indicated that in addition to TGF-β1 pathway, there was another pathway involved in sEVs-inducing Treg.

Several studies have shown that cancer-derived exosomes promote Treg expansion, enhance suppressor function, induce CD8+ T cells apoptosis, and inhibit cytotoxicity of natural killer cells ([@bib3]; [@bib16]; [@bib82]). Most studies have focused on immune-related signaling molecules in exosomes, and few reports have explored the intrinsic signal transduction and epigenetic programming in T lymphocytes affected by exosomes. Our results showed that the gene set of DNA repair was enriched in sEVs-treated T lymphocytes. Previous research showed that lymphocytes are susceptible to DNA DSB due to programmed chromosomal rearrangements at the antigen receptor locus, whereas Tregs have been shown to be more resistant to DNA damage compared with Teffs ([@bib55]; [@bib8]; [@bib93]). ATM plays a crucial role in DNA DSB monitoring, DDR, and T cell development ([@bib6]; [@bib76]; [@bib48]). We thus hypothesized that ATM activation might be involved in Treg induction. Following experiments showed that sEVs treatment activated ATM and increased the number of foci of the DDR coordinators γ-H2AX, RAD51, RPA2, and 53BP1. This result identified the process of DNA repair in exosomes-treated T lymphocytes. Treatment with the ATM inhibitor KU-60019 reversed the phosphorylation of ATM, down-regulated FOXP3 expression, and reduced the CD4+CD25^high^FOXP3+ Treg proportion during sEVs stimulation. These findings suggest that DNA repair and DNA damage-induced ATM activation are essential to induction of Tregs by sEVs.

In addition to DNA repair, metabolism-related gene sets such as Glycolysis and Oxidative Phosphorylation and metabolic KEGG pathways were enriched in sEVs-treated T lymphocytes. This finding is similar to that in previous studies that reported that induced CD4+ Tregs are characterized by mixed metabolism including glycolysis, lipid oxidation, and oxidative phosphorylation ([@bib59]; [@bib78]). As a metabolic regulator, AMPK has been reported to convert metabolism from the energy-demanding pathway to energy-generating mechanisms including glycolysis, oxidative phosphorylation, and autophagy ([@bib31]; [@bib99]; [@bib28]; [@bib40]). In our study, ATM induced AMPK activation following sEVs-induced DNA damage. Our findings were in line with the point of previous studies, which also reported that AMPK is activated by ATM to promote autophagy and regulate DNA damage and T cell senescence ([@bib26]; [@bib44]; [@bib46]). This result suggested that AMPK might serve as a connector for DNA damage repair and energy metabolism switching.

SIRTs have been reported to form an energy sensing network with AMPK in metabolic programming and also to serve as key regulators in the inflammatory response and immune reprograming ([@bib96]; [@bib12]; [@bib98]; [@bib87]; [@bib50]). SIRT1, SIRT2, and SIRT6 exhibit anti-inflammatory properties via suppression of pro-inflammatory cytokine expression and NF-κB-dependent gene expression ([@bib47]; [@bib91]; [@bib45]). Moreover, SIRTs also regulate FOXO1A and FOXO3A ([@bib9]; [@bib37]; [@bib25]), which cooperatively induce FOXP3 expression and control the differentiation of Tregs ([@bib63]; [@bib29]). We found that SIRT1/2/6 regulated the expressions of FOXO1A, FOXO3A, and FOXP3 following AMPK activation in sEVs-treated T lymphocytes. This finding provided a supplement for AMPK and SIRTs participating in immunometabolic reprogramming.

As EVs, exosomes (sEVs) can reach target tissues earlier than cancer cells through body fluids. PC cells are characterized as highly prone to invade lymph nodes. In paired normal and metastatic lymph nodes from 20 patients with PC, we found the highly expressed FOXO1A, FOXO3A, and FOXP3 in metastatic lymph nodes and further identified the positive correlations between the expression of FOXP3 and the expressions of FOXO1A and FOXO3A. These results suggested that highly expressed FOXO1A and FOXO3A in lymph nodes might be a sign of immune tolerance.

In conclusion, our results showed that PC cells-derived sEVs promoted Treg expansion and impaired the cytotoxicity of induced T lymphocytes against PC cells. RNA-seq and GSEA found that gene sets of DDR and metabolic alteration were involved in sEVs-treated T lymphocytes. Furthermore, sEVs-induced upregulation of FOXP3 expression and Treg promotion were mediated by the ATM-AMPK-SIRT1/2/6-FOXO1A/FOXO3A axis. These effects of cancer-derived sEVs on cellular immunity appear to be an important mechanism for immune evasion in PC.

Limitations of the Study {#sec3.1}
------------------------

Our study was performed *in vitro*. Although we simulated the stimulation of T lymphocytes by PC cells-derived sEVs *in vitro*, the *in vitro* culture environment is different from the human tumor microenvironment. The complexity of the pancreatic tumor microenvironment may potentially limit the translational value of our conclusions. Besides, our study was limited only to use PC cell lines such as BxPC-3 and PANC-1. These cells are also different from primary tumor cells. Therefore, further mouse models or organoid models of PC are needed to validate our findings in *in vitro* settings.
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